Open access · US-GOV
via ClinicalTrials.gov Clinical trial
A Safety and Efficacy Study of MSI-1256F (Squalamine Lactate) To Treat "Wet" Age-Related Macular Degeneration
Authors not listed
Genaera Corporation · 2004
Abstract
Age-Related Macular Degeneration (AMD) is a degenerative eye disease of the retina that causes a progressive loss of central vision. AMD is the leading cause of legal blindness among adults age 50 or older in the Western world. AMD presents in two different types - "dry" and the more severe "wet" form. Wet AMD is caused by the growth of abnormal blood vessels in the macula. Squalamine lactate is an investigational drug that may prevent the growth of these abnormal blood vessels. This study will test the safety and efficacy of Squalamine in the treatment of AMD.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- ClinicalTrials.gov
- Canonical
- link ↗
- Fetched
- 2026-11-08 MST
Cite this
APA
Anonymous. (2004). A Safety and Efficacy Study of MSI-1256F (Squalamine Lactate) To Treat "Wet" Age-Related Macular Degeneration. <em>Genaera Corporation</em>. https://clinicaltrials.gov/study/NCT00089830
Vancouver
Anonymous. A Safety and Efficacy Study of MSI-1256F (Squalamine Lactate) To Treat "Wet" Age-Related Macular Degeneration. Genaera Corporation. 2004.
BibTeX
@misc{anon2004ASafet,
title = {A Safety and Efficacy Study of MSI-1256F (Squalamine Lactate) To Treat "Wet" Age-Related Macular Degeneration},
author = {Anonymous},
journal = {Genaera Corporation},
year = {2004},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Ohr Pharmaceutical Inc. 2012
Open access · US-GOV
Phase II Study of the Efficacy and Safety of Squalamine Lactate Ophthalmic Formulation 0.2% BID in Subjects With Neovascular AMD.
Xiaodong Sun 2016
Open access · US-GOV
A Multicenter Study Comparing Efficacy and Safety of " Treat-and-Extend" Regimen Versus "Pro Re Nata" Regimen of Conbercept in Neovascular Age-related Macular Degeneration
Institut de la Macula y la Retina 2010
Open access · US-GOV
FUSION Regimen: A Disease Activity Guided Treatment Algorithm With Ranibizumab in naïve Subjects With Exudative Age-related Macular Degeneration
Advanced Drug Delivery Reviews 2005
Citation only
Wet age-related macular degeneration
Allergan 2007
Open access · US-GOV
Safety and Efficacy of a New Treatment as Adjunctive Therapy to Anti-vascular Endothelial Growth Factor (Anti-VEGF) Treatment in Patients With Age-Related Macular Degeneration (AMD)
New England Journal of Medicine 2021
Preprint · OA